Table 3 Clinicopathologic characteristics of the patients who did not receive secondary debulking surgery
Characteristics | All (n = 118) | Extended chemotherapy (n = 51) | Standard chemotherapy (n = 67) | P |
|---|---|---|---|---|
Age at initial diagnosis, years | 56.1 ± 10.0 | 54.8 ± 9.0 | 57.1 ± 10.6 | 0.208 |
Age at 1st recurrence, years | 57.9 ± 9.9 | 56.4 ± 9.0 | 59.0 ± 10.5 | 0.159 |
Primary site of disease | 0.499 | |||
Ovary | 107 (90.7) | 45 (88.2) | 62 (92.5) | |
Tube | 3 (2.5) | 1 (2.0) | 2 (3.0) | |
Peritoneum | 8 (6.8) | 5 (9.8) | 3 (4.5) | |
Histologic type | 0.381 | |||
Serous | 106 (89.8) | 46 (90.2) | 60 (89.6) | |
Endometrioid | 6 (5.1) | 3 (5.9) | 3 (4.5) | |
Mucinous | 3 (2.5) | 2 (3.9) | 1 (1.5) | |
Clear cell | 3 (2.5) | 0 | 3 (4.5) | |
Mixed | ||||
Grade | 0.113 | |||
1 | 2 (1.7) | 2 (3.9) | 0 | |
2 | 6 (5.1) | 1 (2.0) | 5 (7.5) | |
3 | 110 (93.2) | 48 (94.1) | 62 (92.5) | |
FIGO stage | 0.686 | |||
I-II | 7 (5.9) | 4 (7.8) | 3 (4.5) | |
III | 78 (66.1) | 34 (66.7) | 44 (65.7) | |
IV | 33 (28.0) | 13 (25.5) | 20 (29.9) | |
Primary treatment strategy | 0.625 | |||
PDS | 86 (72.9) | 36 (70.6) | 50 (74.6) | |
NAC | 32 (27.1) | 15 (29.4) | 17 (25.4) | |
Results of initial debulking surgery | 0.036 | |||
Complete gross resection | 59 (50.0) | 21 (41.2) | 38 (56.7) | |
Residual tumor <1 cm | 32 (27.1) | 20 (39.2) | 12 (17.9) | |
Residual tumor ≥1 cm | 27 (22.9) | 10 (19.6) | 17 (25.4) | |
Platinum-free interval, months | ||||
Median (range) | 12.2 (6.0–87.9) | 11.0 (6.2–87.9) | 12.7 (6.0–57.8) | 0.059 |
6–12, partially platinum-sensitive | 55 (46.6) | 27 (52.9) | 28 (41.8) | 0.229 |
≥12, totally platinum-sensitive | 63 (53.4) | 24 (47.1) | 39 (58.2) | |
CA-125 at 1st recurrence, IU/mL | 0.145 | |||
Median (range) | 93.3 (7.9–6290.0) | 107.9 (12.0–6290.0) | 92.9 (7.9–1908.0) | |
Residual tumor on CT after #6 | 0.446 | |||
≥0.5 cm and <1 cm | 57 (48.3) | 27 (52.9) | 30 (44.8) | |
≥1 cm and <2 cm | 47 (39.8) | 17 (33.3) | 30 (44.8) | |
≥2 cm | 14 (11.9) | 7 (13.7) | 7 (10.4) | |
CA-125 after #6, IU/mL | 0.087 | |||
Median (range) | 12.7 (1.1–289.7) | 14.0 (1.1–249.0) | 11.0 (1.1–289.7) | |
Maintenance therapy | ||||
No | 90 (76.3) | 45 (88.2) | 45 (67.2) | 0.008 |
Yes | 28 (23.7) | 6 (11.8) | 22 (32.8) | |
Bevacizumab | 23 (19.5) | 5 (9.8) | 18 (26.9) | >0.999 |
Olaparib | 5 (4.2) | 1 (2.0) | 4 (6.0) | |
Germline BRCA1/2 gene test | ||||
Not performed | 49 (41.5) | 23 (45.1) | 26 (38.8) | 0.492 |
Performed | 69 (58.5) | 28 (54.9) | 41 (61.2) | |
Wild-type | 47 (39.8) | 20 (39.2) | 27 (40.3) | 0.626 |
Mutation | 22 (18.6) | 8 (15.7) | 14 (20.9) | |